Log in

Relevant bibliographies by topics / Liquid Biopsy; Precision Oncology; Clinical Management / Journal articles

To see the other types of publications on this topic, follow the link: Liquid Biopsy; Precision Oncology; Clinical Management.

Journal articles on the topic 'Liquid Biopsy; Precision Oncology; Clinical Management'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Liquid Biopsy; Precision Oncology; Clinical Management.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tan, Wan Ying, Snigdha Nagabhyrava, Olivia Ang-Olson, et al. "Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology." Current Issues in Molecular Biology 46, no. 7 (2024): 6533–65. http://dx.doi.org/10.3390/cimb46070390.

Full text

Abstract:

Technological advancements in cell-free DNA (cfDNA) liquid biopsy have triggered exponential growth in numerous clinical applications. While cfDNA-based liquid biopsy has made significant strides in personalizing cancer treatment, the exploration and translation of epigenetics in liquid biopsy to clinical practice is still nascent. This comprehensive review seeks to provide a broad yet in-depth narrative of the present status of epigenetics in cfDNA liquid biopsy and its associated challenges. It highlights the potential of epigenetics in cfDNA liquid biopsy technologies with the hopes of enha

APA, Harvard, Vancouver, ISO, and other styles

2

Akhoundova, D., J. Mosquera Martinez, L. E. Musmann, et al. "The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer." Journal of Clinical Medicine 9, no. 11 (2020): 3674. http://dx.doi.org/10.3390/jcm9113674.

Full text

Abstract:

Liquid biopsy is a rapidly emerging tool of precision oncology enabling minimally invasive molecular diagnostics and longitudinal monitoring of treatment response. For the clinical management of advanced stage lung cancer patients, detection and quantification of circulating tumor DNA (ctDNA) is now widely adopted into clinical practice. Still, interpretation of results and validation of ctDNA-based treatment decisions remain challenging. We report here our experience implementing liquid biopsies into the clinical management of lung cancer. We discuss advantages and limitations of distinct ctD

APA, Harvard, Vancouver, ISO, and other styles

3

Durole, Payal* S. Waghmare M. Joshi Gangalwar Amey Chavan Siddhesh Chondhe Nikita. "Liquid Biopsies: Revolutionizing Cancer Diagnosis and Prognosis." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 1724–43. https://doi.org/10.5281/zenodo.15382783.

Full text

Abstract:

Liquid biopsy, consisting in the non-invasive analysis of circulating tumor-derived material (the Tumor Circulome), represents an innovative tool in precision oncology to overcome current limitations associated with tissue biopsies. Within the tumor circulome, ctDNA and CTCs are the only components whose clinical application is FDA-cleared. Extracellular vesicles, ctRNA and tumor-educated platelets are relatively novel tumor circulome constituents with promising potential at each stage of cancer management. Here, we discuss the clinical applications of each element of the tumor circulome and t

APA, Harvard, Vancouver, ISO, and other styles

4

von Felden, Johann, Teresa Garcia-Lezana, Kornelius Schulze, Bojan Losic, and Augusto Villanueva. "Liquid biopsy in the clinical management of hepatocellular carcinoma." Gut 69, no. 11 (2020): 2025–34. http://dx.doi.org/10.1136/gutjnl-2019-320282.

Full text

Abstract:

With increasing knowledge on molecular tumour information, precision oncology has revolutionised the medical field over the past years. Liquid biopsy entails the analysis of circulating tumour components, such as circulating tumour DNA, tumour cells or tumour-derived extracellular vesicles, and has thus come as a handy tool for personalised medicine in many cancer entities. Clinical applications under investigation include early cancer detection, prediction of treatment response and molecular monitoring of the disease, for example, to comprehend resistance patterns and clonal tumour evolution.

APA, Harvard, Vancouver, ISO, and other styles

5

Bertoli, Elisa, Elisa De Carlo, Debora Basile, et al. "Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications." International Journal of Molecular Sciences 24, no. 13 (2023): 10803. http://dx.doi.org/10.3390/ijms241310803.

Full text

Abstract:

Tissue biopsy is essential for NSCLC diagnosis and treatment management. Over the past decades, liquid biopsy has proven to be a powerful tool in clinical oncology, isolating tumor-derived entities from the blood. Liquid biopsy permits several advantages over tissue biopsy: it is non-invasive, and it should provide a better view of tumor heterogeneity, gene alterations, and clonal evolution. Consequentially, liquid biopsy has gained attention as a cancer biomarker tool, with growing clinical applications in NSCLC. In the era of precision medicine based on molecular typing, non-invasive genotyp

APA, Harvard, Vancouver, ISO, and other styles

6

Muinelo-Romay, Laura, Carlos Casas-Arozamena, and Miguel Abal. "Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology." International Journal of Molecular Sciences 19, no. 8 (2018): 2311. http://dx.doi.org/10.3390/ijms19082311.

Full text

Abstract:

The identification of new molecular targets and biomarkers associated with high risk of recurrence and response to therapy represents one of the main clinical challenges in the management of advanced disease in endometrial cancer. In this sense, the field of liquid biopsy has emerged as a great revolution in oncology and is considered “the way” to reach personalised medicine. In this review, we discuss the promising but already relatively limited advances of liquid biopsy in endometrial cancer compared to other types of tumours like breast, colorectal or prostate cancer. We present recent data

APA, Harvard, Vancouver, ISO, and other styles

7

Nagayama, Satoshi, Siew-Kee Low, Kazuma Kiyotani, and Yusuke Nakamura. "Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy." Cancers 13, no. 19 (2021): 4803. http://dx.doi.org/10.3390/cancers13194803.

Full text

Abstract:

In the field of colorectal cancer (CRC) treatment, diagnostic modalities and chemotherapy regimens have progressed remarkably in the last two decades. However, it is still difficult to identify minimal residual disease (MRD) necessary for early detection of recurrence/relapse of tumors and to select and provide appropriate drugs timely before a tumor becomes multi-drug-resistant and more aggressive. We consider the leveraging of in-depth genomic profiles of tumors as a significant breakthrough to further improve the overall prognosis of CRC patients. With the recent technological advances in m

APA, Harvard, Vancouver, ISO, and other styles

8

Lin, Chen, Xuzhu Liu, Bingyi Zheng, Rongqin Ke, and Chi-Meng Tzeng. "Liquid Biopsy, ctDNA Diagnosis through NGS." Life 11, no. 9 (2021): 890. http://dx.doi.org/10.3390/life11090890.

Full text

Abstract:

Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains information of genetic alterations. Compared to tissue biopsy, liquid biopsy possesses great advantages such as a less demanding procedure, minimal invasion, ease of frequent sampling, and less sampling bias. Next-generation sequencing (NGS) methods have come to a point that both the cost and performance are suitable for clinical diagnosis. Thus, profi

APA, Harvard, Vancouver, ISO, and other styles

9

Tao, Jessica, Jenna VanLiere Canzoniero, Maria Fatteh, et al. "Liquid biopsy-informed precision oncology study to evaluate utility of plasma genomic profiling for therapy selection." Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS1616. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps1616.

Full text

Abstract:

TPS1616 Background: Liquid biopsies have enabled a transformation in the management of patients with cancer as they have the potential to detect, characterize, and monitor tumor burden. However, the increasing complexity involved in the integration of genomic data into clinical practice has presented challenges with the practical implementation of liquid biopsies in clinical cancer care. To address these challenges, multidisciplinary teams comprised of experts within oncology, genetics, pathology, and informatics have created Molecular Tumor Boards (MTBs), which can improve clinical outcomes f

APA, Harvard, Vancouver, ISO, and other styles

10

Fernandes Marques, Joana, Joana Pereira Reis, Gabriela Fernandes, Venceslau Hespanhol, José Carlos Machado, and José Luís Costa. "Circulating Tumor DNA: A Step into the Future of Cancer Management." Acta Cytologica 63, no. 6 (2019): 456–65. http://dx.doi.org/10.1159/000492917.

Full text

Abstract:

Liquid biopsy was introduced to the oncology field with the promise of revolutionizing the management of cancer patients, minimizing the exposure to invasive procedures such as tissue biopsy, and providing reliable information regarding therapy response and detection of disease relapse. Despite the significant increase in the number of published studies on circulating tumor DNA (ctDNA) in the past years, the emphasis of most studies is on the development of new technologies or on the clinical utility of ctDNA. This leaves a clear gap of knowledge concerning the biology of ctDNA, such as the fu

APA, Harvard, Vancouver, ISO, and other styles

11

Cani, Andi K., and Simpa S. Salami. "Recent Advances in Blood-Based Liquid Biopsy Approaches in Prostate Cancer." Cancer Journal 29, no. 4 (2023): 220–25. http://dx.doi.org/10.1097/ppo.0000000000000672.

Full text

Abstract:

Abstract The advent of high-throughput technologies has enabled the analysis of minute amounts of tumor-derived material purified from body fluids, termed “liquid biopsies.” Prostate cancer (PCa) management, like in many other cancer types, has benefited from liquid biopsies at several stages of the disease. Although initially describing circulating tumor cells in blood, the term “liquid biopsy” has come to more prominently include cell-free, circulating tumor DNA, as well as RNA, proteins, and other molecules. They provide tumor molecular information representing the entire, often-heterogeneo

APA, Harvard, Vancouver, ISO, and other styles

12

Dalal, S., and D. Jhala. "Incidence of Androgen Receptor and DNA Repair Gene Mutations in Advanced Solid Malignancies: Clinical Impact of Liquid Biopsy at Veteran Affairs Medical Center." American Journal of Clinical Pathology 154, Supplement_1 (2020): S145—S146. http://dx.doi.org/10.1093/ajcp/aqaa161.318.

Full text

Abstract:

Abstract Introduction/Objective The advent of Liquid biopsy targeting genetic mutations in solid tumors is a major milestone in field of precision oncology. This minimally invasive, novel revolutionary technique analyses circulating tumor cells (CTC) in peripheral blood and detects signature genomic alterations. DNA repair gene (DDR) mutations have been reported in 25-40% of prostatic cancers and &gt;50% of non-small cell lung cancers (NSCLC), being more common in late-stage and hormone refractory prostate cancers. One of the DDR, especially Tp53 has been found to be associated with poor p

APA, Harvard, Vancouver, ISO, and other styles

13

Researcher. "EMERGING CIRCULATING AND TISSUE-BASED BIOMARKERS IN EARLY DETECTION, PROGNOSTIC EVALUATION, AND PERSONALIZED MANAGEMENT OF COMPLEX PATHOLOGICAL CONDITIONS." International Journal of Pathology (IJPA) 3, no. 1 (2025): 1–8. https://doi.org/10.5281/zenodo.14799281.

Full text

Abstract:

The increasing prevalence of complex pathological conditions necessitates the development of effective biomarkers for early detection, prognosis, and personalized therapeutic strategies. Circulating and tissue-based biomarkers offer non-invasive and specific means for disease characterization, allowing precision medicine approaches. This paper reviews recent advancements in biomarker research, highlighting emerging circulating and tissue-based markers, detection technologies, and their clinical implications. Furthermore, we examine their roles in oncology, cardiovascular diseases, and neurolog

APA, Harvard, Vancouver, ISO, and other styles

14

Fagbemi Oluwaseyi Ajibola, Toluwani Samuel Ogunmoyero, Taiwo Bakare-Abidola, et al. "Breakthroughs and challenges in liquid biopsy technologies for cancer diagnosis and treatment monitoring." World Journal of Biology Pharmacy and Health Sciences 22, no. 1 (2025): 112–38. https://doi.org/10.30574/wjbphs.2025.22.1.0327.

Full text

Abstract:

Cancer remains a leading global health challenge, with early detection and precise monitoring playing a crucial role in improving patient outcomes. Traditional tissue biopsies, while essential for diagnosis, are invasive, limited in scope, and often fail to capture tumor heterogeneity or track disease progression dynamically. Liquid biopsy technologies have emerged as a transformative alternative, offering a minimally invasive approach to cancer detection and management by analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, and tumor-derived exosome

APA, Harvard, Vancouver, ISO, and other styles

15

Ahluwalia, Pankaj, Kalyani Ballur, Tiffanie Leeman, et al. "Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine." Cancers 16, no. 3 (2024): 480. http://dx.doi.org/10.3390/cancers16030480.

Full text

Abstract:

Colorectal cancer (CRC) is one of the most heterogeneous and deadly diseases, with a global incidence of 1.5 million cases per year. Genomics has revolutionized the clinical management of CRC by enabling comprehensive molecular profiling of cancer. However, a deeper understanding of the molecular factors is needed to identify new prognostic and predictive markers that can assist in designing more effective therapeutic regimens for the improved management of CRC. Recent breakthroughs in single-cell analysis have identified new cell subtypes that play a critical role in tumor progression and cou

APA, Harvard, Vancouver, ISO, and other styles

16

Brandt, Anna, Benjamin Thiele, Christoph Schultheiß, Eveline Daetwyler, and Mascha Binder. "Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma." Cancers 15, no. 7 (2023): 2051. http://dx.doi.org/10.3390/cancers15072051.

Full text

Abstract:

Tumors shed cell-free DNA (cfDNA) into the plasma. “Liquid biopsies” are a diagnostic test to analyze cfDNA in order to detect minimal residual cancer, profile the genomic tumor landscape, and monitor cancers non-invasively over time. This technique may be useful in patients with head and neck squamous cell carcinoma (HNSCC) due to genetic tumor heterogeneity and limitations in imaging sensitivity. However, there are technical challenges that need to be overcome for the widespread use of liquid biopsy in the clinical management of these patients. In this review, we discuss our current understa

APA, Harvard, Vancouver, ISO, and other styles

17

Millan, Braden, Lauren Loebach, Ruben Blachman-Braun, et al. "Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance." Current Oncology 32, no. 6 (2025): 359. https://doi.org/10.3390/curroncol32060359.

Full text

Abstract:

Molecular testing in renal cell carcinoma (RCC) has allowed for a better understanding of the biology of both sporadic and hereditary diseases, where genetic testing is currently recommended in the guidelines for a select population with risk factors. Historically, screening, surveillance, and management decisions were based solely on clinicopathologic data; however, we now know that molecular profiling can enhance decision making, altering the treatment plan, approach, or selection of systemic therapy and enhancing the delivery of precision oncologic care. Advances and the increasing availabi

APA, Harvard, Vancouver, ISO, and other styles

18

Ayesha Liaqat, Mohsin Saleem Ghouri, Raheela Shehzadi, et al. "Nano-Engineering for Precision Oncology Unraveling Molecular Mechanisms and Pioneering Revolutionary Cancer Therapies." Indus Journal of Bioscience Research 3, no. 3 (2025): 9–18. https://doi.org/10.70749/ijbr.v3i3.810.

Full text

Abstract:

With previously unheard-of improvements in cancer detection, therapy, and monitoring, nano-engineering has become a game-changer in precision oncology. Researchers can create nanoscale drug delivery systems that maximize therapeutic efficacy and reduce systemic toxicity by utilizing nanotechnology. With an emphasis on targeted drug delivery, tumor microenvironment manipulation, and nanocarrier-mediated immunotherapy, this study investigates the molecular processes underlying nano-engineered therapeutics. By increasing specificity and lowering side effects, innovations including photothermal an

APA, Harvard, Vancouver, ISO, and other styles

19

Martin-Alonso, Carmen, Shervin Tabrizi, Kan Xiong, et al. "Abstract PR007: A liposomal priming agent increases the sensitivity of liquid biopsies." Cancer Prevention Research 16, no. 1_Supplement (2023): PR007. http://dx.doi.org/10.1158/1940-6215.precprev22-pr007.

Full text

Abstract:

Abstract Liquid biopsy measurements, such as analysis of circulating tumor DNA (ctDNA) shed by cancer cells, have garnered significant attention for their potential to empower the field of precision oncology. Given that ctDNA tests could enable minimally invasive monitoring and molecular profiling of disease, they are being investigated for use in earlier detection via pan-cancer screening tests, for tracking tumor evolution to inform therapy selection, and for making treatment decisions during minimal residual disease surveillance. However, a typical blood draw carries ultra-low levels of ctD

APA, Harvard, Vancouver, ISO, and other styles

20

West, Samuel M., and Nicole Ramlachan. "Abstract C028: Using novel multiomic plasma profiling from liquid biopsies to identify potential signatures for disease diagnostics in late-stage non-small cell lung cancer (NSCLC) in Trinidad and Tobago." Cancer Epidemiology, Biomarkers & Prevention 32, no. 12_Supplement (2023): C028. http://dx.doi.org/10.1158/1538-7755.disp23-c028.

Full text

Abstract:

Abstract Lung cancer is the leading cause of cancer-associated deaths in North America, with the vast majority being non-small cell lung cancer (NSCLC) with a five-year survival rate of only 24%. Non-invasive discovery of biomarkers associated with early-diagnosis of NSCLC can enable precision oncology efforts using liquid biopsy-based multiomic profiling of plasma cell-free DNA. Although tissue biopsies are currently the gold standard for tumor profiling, this method presents many limitations since these are invasive, risky, and sometimes hard to obtain as well as only giving a limited tumor

APA, Harvard, Vancouver, ISO, and other styles

21

Kahana-Edwin, Smadar, James Torpy, Lucy E. Cain, et al. "Quantitative ctDNA Detection in Hepatoblastoma: Implications for Precision Medicine." Cancers 16, no. 1 (2023): 12. http://dx.doi.org/10.3390/cancers16010012.

Full text

Abstract:

Hepatoblastoma is characterized by driver mutations in CTNNB1, making it an attractive biomarker for a liquid biopsy approach utilizing circulating tumor DNA (ctDNA). This prospective observational study sought to ascertain the feasibility of ctDNA detection in patients with hepatoblastoma and explore its associations with established clinical indicators and biomarkers, including serum Alpha-fetoprotein (AFP). We obtained 38 plasma samples and 17 tumor samples from 20 patients with hepatoblastoma. These samples were collected at various stages: 10 at initial diagnosis, 17 during neoadjuvant ch

APA, Harvard, Vancouver, ISO, and other styles

22

Magliocco, Anthony Martin, Roy Khalife, Catherine Wilson, Tara M. Love, and Rama Balaraman. "DelPHI: A novel program to accelerate access to precision oncology in the community oncology setting." Journal of Clinical Oncology 41, no. 16_suppl (2023): e18713-e18713. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18713.

Full text

Abstract:

e18713 Background: It has been well recognized that the rapid advances in precision oncology have not fully been translated into improved access for community cancer programs in the USA, where as much as 95% of oncological assessment and treatment occurs. To address this growing gap, Protean BioDiagnostics and Roche Information Solutions have created a novel project to improve the Delivery of Precision Health Information (DelPHI) to community-based oncology programs using an innovative precision oncology testing system (MAPS™) integrated with a digital decision support and telemedicine framewo

APA, Harvard, Vancouver, ISO, and other styles

23

Rafanan, John, Nabih Ghani, Sarah Kazemeini, Ahmed Nadeem-Tariq, Ryan Shih, and Thomas A. Vida. "Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment." International Journal of Molecular Sciences 26, no. 3 (2025): 917. https://doi.org/10.3390/ijms26030917.

Full text

Abstract:

Advances in neuro-oncology have transformed the diagnosis and management of brain tumors, which are among the most challenging malignancies due to their high mortality rates and complex neurological effects. Despite advancements in surgery and chemoradiotherapy, the prognosis for glioblastoma multiforme (GBM) and brain metastases remains poor, underscoring the need for innovative diagnostic strategies. This review highlights recent advancements in imaging techniques, liquid biopsies, and artificial intelligence (AI) applications addressing current diagnostic challenges. Advanced imaging techni

APA, Harvard, Vancouver, ISO, and other styles

24

Hallermayr, Ariane, Verena Steinke-Lange, Holger Vogelsang, et al. "Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management." Cancers 14, no. 3 (2022): 851. http://dx.doi.org/10.3390/cancers14030851.

Full text

Abstract:

Circulating tumor DNA (ctDNA) is a promising liquid biopsy (LB) marker to support clinical decisions in precision medicine. For implementation into routine clinical practice, clinicians need precise ctDNA level cutoffs for reporting residual disease and monitoring tumor burden changes during therapy. We clinically validated the limit of blank (LOB) and the limit of quantification (LOQ) of assays for the clinically most relevant somatic variants BRAF p.V600E and KRAS p.G12/p.G13 in colorectal cancer (CRC) in a study cohort encompassing a total of 212 plasma samples. We prove that residual disea

APA, Harvard, Vancouver, ISO, and other styles

25

Ouyang, Dongfang, Ningxin Ye, Kun Yang, et al. "Precision Isolation of Circulating Leukemia Cells in Chronic Myelogenous Leukemia Patients Using a Novel Microfluidic Device and Its Clinical Applications." Cancers 15, no. 23 (2023): 5696. http://dx.doi.org/10.3390/cancers15235696.

Full text

Abstract:

Chronic Myelogenous Leukemia (CML) is a prevalent hematologic malignancy characterized by the malignant transformation of myeloid cells and their proliferation in the peripheral blood. The management of CML poses significant challenges, particularly in detecting and eradicating minimal residual disease, which is crucial for preventing relapse and improving survival outcomes. Traditional minimal residual disease detection methods, such as bone marrow aspiration, are invasive and have limitations which include the potential for sampling errors and false negatives. This study introduces a novel l

APA, Harvard, Vancouver, ISO, and other styles

26

Wu, Ting-Miao, Ji-Bin Liu, Yu Liu, et al. "Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control." Cancer Control 27, no. 3 (2020): 107327482093480. http://dx.doi.org/10.1177/1073274820934805.

Full text

Abstract:

Traditional methods of cancer treatment are usually based on the morphological and histological diagnosis of tumors, and they are not optimized according to the specific situation. Precision medicine adjusts the existing treatment regimen based on the patient’s genomic information to make it most suitable for patients. Detection of genetic mutations in tumors is the basis of precise cancer medicine. Through the analysis of genetic mutations in patients with cancer, we can tailor the treatment plan for each patient with cancer to maximize the curative effect, minimize damage to healthy tissues,

APA, Harvard, Vancouver, ISO, and other styles

27

Park, Juhee, Chaeeun Lee, Jung Seop Eom, Mi-Hyun Kim, and Yoon-Kyoung Cho. "Detection of EGFR Mutations Using Bronchial Washing-Derived Extracellular Vesicles in Patients with Non-Small-Cell Lung Carcinoma." Cancers 12, no. 10 (2020): 2822. http://dx.doi.org/10.3390/cancers12102822.

Full text

Abstract:

The detection of epidermal growth factor receptor (EGFR) mutation, based on tissue biopsy samples, provides a valuable guideline for the prognosis and precision medicine in patients with lung cancer. In this study, we aimed to examine minimally invasive bronchial washing (BW)-derived extracellular vesicles (EVs) for EGFR mutation analysis in patients with lung cancer. A lab-on-a-disc equipped with a filter with 20-nm pore diameter, Exo-Disc, was used to enrich EVs in BW samples. The overall detection sensitivity of EGFR mutations in 55 BW-derived samples was 89.7% and 31.0% for EV-derived DNA

APA, Harvard, Vancouver, ISO, and other styles

28

Grosu, Daniel S., Ilya Chorny, Kristina M. Kruglyak, et al. "Abstract 3377: Liquid biopsy analysis reveals orthologs of actionable human cancer variants in dogs." Cancer Research 83, no. 7_Supplement (2023): 3377. http://dx.doi.org/10.1158/1538-7445.am2023-3377.

Full text

Abstract:

Abstract Genotype-matched therapeutics have become widely adopted in the management of human cancers and can be guided by testing tumor tissue or cell-free DNA from plasma. OncoKB (Oncology Knowledge Base) is the first FDA-recognized database that contains information about these targetable somatic variants and corresponding therapeutic agents, including levels of evidence. Many of the human OncoKB variants have orthologs in the canine genome. This study was conducted to determine the feasibility of detecting these orthologs in dogs using liquid biopsy. This study involved two cohorts: The fir

APA, Harvard, Vancouver, ISO, and other styles

29

Lonardi, Sara, Clara Montagut, Filippo Pietrantonio, et al. "The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients." Journal of Clinical Oncology 38, no. 15_suppl (2020): TPS4124. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps4124.

Full text

Abstract:

TPS4124 Background: Moving stage III Colon Cancer (CC) into the precision medicine space is a priority in view of the lack of molecular markers driving adjuvant treatment. Retrospective studies have demonstrated the tremendous prognostic impact of circulating tumor DNA (ctDNA) analysis after curative intent surgery, and suggested that lack of conversion of ctDNA from detectable to undetectable after adjuvant chemotherapy reflects treatment failure. With these premises, we have designed the PEGASUS trial (NCT04259944). Methods: PEGASUS is a prospective multicentric study designed to prove the f

APA, Harvard, Vancouver, ISO, and other styles

30

Kapelanski-Lamoureux, Audrey, Migmar Tsamchoe, Lucyna Krzywon, et al. "AI-powered multi-omic signature to predict treatment response of patients with colorectal cancer liver metastasis." Journal of Clinical Oncology 41, no. 4_suppl (2023): 252. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.252.

Full text

Abstract:

252 Background: Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in North America with over 50% of CRC patients developing liver metastases (LM) and 90% will die from metastatic disease. CRCLM are categorized into two main histological growth patterns (HGP) lesions: Desmoplastic (DHGP) and Replacement (RHGP). We have previously published that HGPs display distinct patterns of vascularization, local invasion, growth and response to treatment. Resected CRCLM patients with predominantly DHGP metastasis (~45%) receiving anti-VEGF therapy and chemotherapy have more than d

APA, Harvard, Vancouver, ISO, and other styles

31

Taghizadeh, Hossein, and Gerald W. Prager. "Personalized Adjuvant Treatment of Colon Cancer." Visceral Medicine 36, no. 5 (2020): 397–406. http://dx.doi.org/10.1159/000508175.

Full text

Abstract:

<b><i>Introduction:</i></b> Colon cancer (CC) is one of the most frequent malignant diseases. Adjuvant chemotherapy is of utmost importance in the management of localized disease. With the emergence of precision medicine, treatment approaches are becoming increasingly personalized and complex. This review contributes to a broader understanding of the role and relevance of personalized adjuvant treatment strategies in colon carcinoma, and summarizes the current status in this disease entity. <b><i>Methods:</i></b> We searched the websites Clinical

APA, Harvard, Vancouver, ISO, and other styles

32

Shore, Neal D., Christopher Craver, Simon Blanc, et al. "Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 42, no. 4_suppl (2024): 210. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.210.

Full text

Abstract:

210 Background: Routine germline and somatic testing is recommended by professional guidelines as standard of care for all mCRPC patients since the approvals of poly ADP ribose polymerase inhibitors (PARPi) for treatment in those with tumors harboring select HRRm. Yet, analyses suggest that many mCRPC patients are not offered testing and thus patients with HRRm+ tumors may not have the shared decision-making opportunity to consider PARPi therapy. We reviewed HRR testing and treatment patterns within a real-world cohort of mCRPC patients to identify potential clinical practice gaps. Methods: Th

APA, Harvard, Vancouver, ISO, and other styles

33

Ravindran, Ramya, Ramadas Naik, Kavitha KP, and Vipin Viswanath. "Peripheral Blood Circulatory Tumour Cells Enumeration as A Non-Invasive Biomarker in Breast Cancer Diagnosis: A Case-Control Study." Journal of Neonatal Surgery 14, no. 25S (2025): 1060–69. https://doi.org/10.63682/jns.v14i25s.6731.

Full text

Abstract:

Aim and Background: Breast cancer is one of the most prevalent malignancy among women worldwide, and its early detection remains a challenge. Circulating tumour cells (CTCs) are emerging as promising biomarkers for the diagnosis, prognosis, and monitoring of cancer. This study aims to assess the diagnostic performance of CK-positive and HER2-positive CTCs in breast cancer patients and healthy controls. Methods: This prospective case-control study involved 60 breast cancer patients (cases) and 60 age-matched healthy individuals (controls). Peripheral blood samples were collected prior to any on

APA, Harvard, Vancouver, ISO, and other styles

34

Nickols, Nicholas George, Kara Noelle Maxwell, Kyung Min Lee, et al. "Frequencies of actionable alterations found by somatic tumor sequencing in veterans with metastatic prostate cancer." Journal of Clinical Oncology 40, no. 6_suppl (2022): 178. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.178.

Full text

Abstract:

178 Background: Prostate cancer comprises one third of male Veteran cancers and is their second leading cause of cancer death. Metastatic prostate cancer is lethal. Next Generation Sequencing (NGS) of somatic tumors is recommended for metastatic prostate to identify actionable alterations targeted with approved therapies. Veterans with prostate cancers harboring alterations in genes involved in the DNA damage response (e.g. BRCA1/2) or high microsatellite instability (MSI-High) may be eligible for PARP inhibitors or checkpoint blockade immunotherapy, respectively. Potential candidates may be i

APA, Harvard, Vancouver, ISO, and other styles

35

Hoffman, Robert, Louis Ignarro, Tim Hunt, et al. "The Institute for Personalized Medicine in Georgia: A Hub of Scientific Innovation and Global Healthcare Leadership." Journal of Cancer Research 2, no. 1 (2024): 01–23. https://doi.org/10.64030/2578-3726.02.01.11.

Full text

Abstract:

The Institute for Personalized Medicine of Georgia is a leading healthcare and research institution dedicated to advancing personalized healthcare, clinical research, and medical education. This comprehensive review highlights the Institute’s pivotal role in transforming precision medicine in Georgia and establishing itself on the global stage through interdisciplinary healthcare, collaborative research, and education. With a mission to deliver individualized medical care, the Institute provides state-of-the-art treatment and research across a range of fields, including oncology, medical genet

APA, Harvard, Vancouver, ISO, and other styles

36

Maheshwari, Udip, Dr Disha Morzaria, Vashishth Maniar, et al. "Experience of personalizing cancer treatment in economically-constrained and resource-restricted community oncology practice in India through cost-effective broad spectrum NGS and survival outcomes: An observational study of 3 years." Journal of Clinical Oncology 42, no. 16_suppl (2024): e15173-e15173. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15173.

Full text

Abstract:

e15173 Background: NGS based mutational findings are increasingly used in oncology practice to personalize treatment strategies. We elucidate the impact of comprehensive genomic profiling and the new avenues it opens for personalized precision medicine. Methods: This was a retrospective study evaluating patients who underwent a cost-effective (<US $1000), inhouse developed comprehensive NGS test. Descriptive data was tabulated & mutational distribution, therapeutic strategies and survival outcomes were evaluated. Results: A total of 336 patients were evaluated from a community oncology

APA, Harvard, Vancouver, ISO, and other styles

37

Haider, Zahra, Linda Köhn, Nicholas Karlowatz, Mikael B. Johansson, and Jonas A. Nilsson. "Abstract 530: UMAP- Personalized lung cancer monitoring platform." Cancer Research 82, no. 12_Supplement (2022): 530. http://dx.doi.org/10.1158/1538-7445.am2022-530.

Full text

Abstract:

Abstract Lung cancer is the leading cause of cancer death, accounting for 1.6 million deaths per year. The prognosis for newly diagnosed cases is overall poor and strongly influenced by clinical stage at time of diagnosis, with dismal survival rates for cases diagnosed at a late stage. However, molecular profiling at diagnosis and advances in precision medicine has vastly improved the clinical management of lung cancer patients. An efficient evaluation of treatment response and early detection of recurrent disease can further improve survival rates. However, response evaluation during treatmen

APA, Harvard, Vancouver, ISO, and other styles

38

Bai, Rilan, Zheng Lv, Xiao Chen, et al. "Precision Detection Technology: Equipping Precision Oncology with Wings." Journal of Oncology 2020 (July 9, 2020): 1–8. http://dx.doi.org/10.1155/2020/9068121.

Full text

Abstract:

In recent years, precision medical detection techniques experienced a rapid transformation from low-throughput to high-throughput genomic sequencing, from multicell promiscuous detection to single-cell precision sequencing. The emergence of liquid biopsy technology has compensated for the many limitations of tissue biopsy, leading to a tremendous transformation in precision detection. Precision detection techniques contribute to monitoring disease development more closely, evaluating therapeutic effects more scientifically, and developing new targets and new drugs. In the future, the role of p

APA, Harvard, Vancouver, ISO, and other styles

39

Batool, Syeda Maheen, Tiffaney Hsia, Sirena K. Khanna, et al. "Decoding vesicle-based precision oncology in gliomas." Neuro-Oncology Advances 4, Supplement_2 (2022): ii53—ii60. http://dx.doi.org/10.1093/noajnl/vdac035.

Full text

Abstract:

Abstract Extracellular vesicles (EVs) represent a valuable tool in liquid biopsy with tremendous clinical potential in diagnosis, prognosis, and therapeutic monitoring of gliomas. Compared to tissue biopsy, EV-based liquid biopsy is a low-cost, minimally invasive method that can provide information on tumor dynamics before, during, and after treatment. Tumor-derived EVs circulating in biofluids carry a complex cargo of molecular biomarkers, including DNA, RNA, and proteins, which can be indicative of tumor growth and progression. Here, we briefly review current commercial and noncommercial met

APA, Harvard, Vancouver, ISO, and other styles

40

Ho, Ho-Yin, Kei-See (Kasey) Chung, Chau-Ming Kan, and Sze-Chuen (Cesar) Wong. "Liquid Biopsy in the Clinical Management of Cancers." International Journal of Molecular Sciences 25, no. 16 (2024): 8594. http://dx.doi.org/10.3390/ijms25168594.

Full text

Abstract:

Liquid biopsy, a noninvasive diagnosis that examines circulating tumor components in body fluids, is increasingly used in cancer management. An overview of relevant literature emphasizes the current state of liquid biopsy applications in cancer care. Biomarkers in liquid biopsy, particularly circulating tumor DNA (ctDNA), circulating tumor RNAs (ctRNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other components, offer promising opportunities for early cancer diagnosis, treatment selection, monitoring, and disease assessment. The implementation of liquid biopsy in precis

APA, Harvard, Vancouver, ISO, and other styles

41

Liszewski, Kathy. "Liquid Biopsy Technologies Hasten Progress in Precision Oncology." Genetic Engineering & Biotechnology News 43, no. 9 (2023): 26–29. http://dx.doi.org/10.1089/gen.43.09.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Yee, Nelson S. "Liquid Biopsy: A Biomarker-Driven Tool towards Precision Oncology." Journal of Clinical Medicine 9, no. 8 (2020): 2556. http://dx.doi.org/10.3390/jcm9082556.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Fernández-Lázaro, Diego, Juan Luis García Hernández, Alberto Caballero García, Alfredo Córdova Martínez, Juan Mielgo-Ayuso, and Juan Jesús Cruz-Hernández. "Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer’s Biomarkers." Diagnostics 10, no. 4 (2020): 215. http://dx.doi.org/10.3390/diagnostics10040215.

Full text

Abstract:

In recent years, there has been an increase in knowledge of cancer, accompanied by a technological development that gives rise to medical oncology. An instrument that allows the implementation of individualized therapeutic strategies is the liquid biopsy. Currently, it is the most innovative methodology in medical oncology. Its high potential as a tool for screening and early detection, the possibility of assessing the patient’s condition after diagnosis and relapse, as well as the effectiveness of real-time treatments in different types of cancer. Liquid biopsy is capable of overcoming the li

APA, Harvard, Vancouver, ISO, and other styles

44

Kolenčík, Drahomír, Stephanie N. Shishido, Pavel Pitule, Jeremy Mason, James Hicks, and Peter Kuhn. "Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges." Cancers 12, no. 6 (2020): 1376. http://dx.doi.org/10.3390/cancers12061376.

Full text

Abstract:

Colorectal carcinoma (CRC) is characterized by wide intratumor heterogeneity with general genomic instability and there is a need for improved diagnostic, prognostic, and therapeutic tools. The liquid biopsy provides a noninvasive route of sample collection for analysis of circulating tumor cells (CTCs) and genomic material, including cell-free DNA (cfDNA), as a complementary biopsy to the solid tumor tissue. The solid biopsy is critical for molecular characterization and diagnosis at the time of collection. The liquid biopsy has the advantage of longitudinal molecular characterization of the

APA, Harvard, Vancouver, ISO, and other styles

45

Kim, Young, Hye Mi Ko, Ye Ri Lee, Kyoung Hoon Suh, Je Ryong Kim, and Jin Sun Lee. "Thioredoxin 1 in blood as a monitoring biomarker for patients with breast cancer post-treatment." Journal of Clinical Oncology 42, no. 16_suppl (2024): e15041-e15041. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15041.

Full text

Abstract:

e15041 Background: The spatial and temporal heterogeneity of tumors in breast cancer pose challenges in precision oncology. Although breast imaging during screening has increased tumor detection and reduced mortality rates, it is limited in tracking minimal residual disease after surgery. Consequently, there is a need for liquid biopsy with easy longitudinal sampling to track real-time changes in tumor characteristics during treatment. Existing biomarkers (CA15-3 and CEA) for post-treatment monitoring are unsatisfactory. This study explores the clinical validity and stability of thioredoxin1 (

APA, Harvard, Vancouver, ISO, and other styles

46

Sanchez, Gisella M., Douglas Chigane, Michelle Lin, Liya Xu, Venkata Yellapantula, and Jesse L. Berry. "Retinoblastoma: Aqueous humor liquid biopsy." Taiwan Journal of Ophthalmology 15, no. 1 (2025): 55–61. https://doi.org/10.4103/tjo.tjo-d-24-00133.

Full text

Abstract:

Abstract: Advances in retinoblastoma (RB) therapy have led to significantly improved ocular preservation rates, consequently limiting access to histologic and genomic information traditionally obtained from enucleated eyes. Moreover, genomic information from enucleated specimens often represents heavily pretreated, refractory disease. The introduction of aqueous humor (AH) biopsy marks a significant milestone in ocular oncology, offering in vivo, real-time tumoral genomic data that can be collected at diagnosis and repeatedly throughout treatment. This liquid biopsy has detected RB1 gene mutat

APA, Harvard, Vancouver, ISO, and other styles

47

Remon, J., R. García-Campelo, E. de Álava, et al. "Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology." Clinical and Translational Oncology 22, no. 6 (2019): 823–34. http://dx.doi.org/10.1007/s12094-019-02211-x.

Full text

Abstract:

Abstract The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is growing considerably. The diagnosis of these genomic alterations can lead to tailored treatment at the onset of disease or on progression and to obtaining additional predictive information on immunotherapy efficacy. However, in up to 25% of cases, the initial tissue biopsy is inadequate for precision oncology and, in many cases, tumour genomic profiling at progression is not possible due to technical limitations of obtaining new tumour tissue specimens. Efficient diagnostic alter

APA, Harvard, Vancouver, ISO, and other styles

48

Mathai, Roshni, Ryali Vidya, B. Reddy, et al. "Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology." Journal of Clinical Medicine 8, no. 3 (2019): 373. http://dx.doi.org/10.3390/jcm8030373.

Full text

Abstract:

Liquid biopsy is a technique that utilizes circulating biomarkers in the body fluids of cancer patients to provide information regarding the genetic landscape of the cancer. It is emerging as an alternative and complementary diagnostic and prognostic tool to surgical biopsy in oncology. Liquid biopsy focuses on the detection and isolation of circulating tumor cells, circulating tumor DNA and exosomes, as a source of genomic and proteomic information in cancer patients. Liquid biopsy is expected to provide the necessary acceleratory force for the implementation of precision oncology in clinical

APA, Harvard, Vancouver, ISO, and other styles

49

Palmirotta, Raffaele, Domenica Lovero, Paola Cafforio, et al. "Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology." Therapeutic Advances in Medical Oncology 10 (January 2018): 175883591879463. http://dx.doi.org/10.1177/1758835918794630.

Full text

Abstract:

Over the last decades, the concept of precision medicine has dramatically renewed the field of medical oncology; the introduction of patient-tailored therapies has significantly improved all measurable outcomes. Liquid biopsy is a revolutionary technique that is opening previously unexpected perspectives. It consists of the detection and isolation of circulating tumor cells, circulating tumor DNA and exosomes, as a source of genomic and proteomic information in patients with cancer. Many technical hurdles have been resolved thanks to newly developed techniques and next-generation sequencing an

APA, Harvard, Vancouver, ISO, and other styles

50

Keup, Corinna, Rainer Kimmig, and Sabine Kasimir-Bauer. "Combinatorial Power of cfDNA, CTCs and EVs in Oncology." Diagnostics 12, no. 4 (2022): 870. http://dx.doi.org/10.3390/diagnostics12040870.

Full text

Abstract:

Liquid biopsy is a promising technique for clinical management of oncological patients. The diversity of analytes circulating in the blood useable for liquid biopsy testing is enormous. Circulating tumor cells (CTCs), cell-free DNA (cfDNA) and extracellular vesicles (EVs), as well as blood cells and other soluble components in the plasma, were shown as liquid biopsy analytes. A few studies directly comparing two liquid biopsy analytes showed a benefit of one analyte over the other, while most authors concluded the benefit of the additional analyte. Only three years ago, the first studies to ex

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!